Genenta Science (GNTA) Stock Price, News & Analysis

Company Overview

Genenta Science is a clinical‐stage biotechnology company focused on developing innovative gene and cell therapies for cancer. Founded as a spin‐off from the San Raffaele Hospital in Milan, Italy, the company leverages a proprietary platform to engineer hematopoietic stem and progenitor cells as vehicles for targeted cytokine delivery within the tumor microenvironment. Genenta’s approach seeks to combine the precision of gene therapy with the systemic reach of cell therapy to achieve sustained, localized anti‐tumor activity.

The company’s core technology, known as SNIP (Selectively INduced Protein), enables conditional expression of therapeutic cytokines such as interferon‐alpha directly at sites of disease. By integrating a molecular “switch” that responds to an orally administered activator, SNIP allows clinicians to control the timing and dosage of cytokine release, potentially reducing systemic toxicity. This platform underpins Genenta’s lead candidate, temferon, which is currently being evaluated in clinical trials for glioblastoma and ovarian cancer.

Genenta Science has pursued a global clinical strategy, initiating studies in Europe and North America in collaboration with leading academic cancer centers. The company’s pipeline also includes preclinical programs targeting other solid tumors and hematological malignancies. In addition to advancing its own research, Genenta has established partnerships with biotechnology firms and research institutions to explore new applications of its inducible gene‐therapy technology across multiple tumor types.

Headquartered in Milan with operations extending to the United States, Genenta Science is led by an experienced management team with deep expertise in oncology, gene therapy, and pharmaceutical development. The leadership group includes professionals who have held senior roles at major biopharmaceutical companies and academic research organizations. Through strategic collaborations and a focused R&D pipeline, Genenta aims to address unmet needs in cancer treatment by delivering precise, controllable immunotherapies.

Key Stats

• Today's Range: $3.80 to $3.98
• 50-Day Range: $3.05 to $5.01
• 52-Week Range: $2.74 to $7.28
• Volume: 5,332 shs
• Average Volume: 16,903 shs
• Market Capitalization: $72.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Buy

Genenta Science Stock Analysis - MarketRank™

Genenta Science scored higher than 53% of companies evaluated by MarketBeat, and ranked 716th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Genenta Science has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genenta Science has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Genenta Science are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.

Price to Book Value per Share Ratio

Genenta Science has a P/B Ratio of 5.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Genenta Science has been sold short.

Short Interest Ratio / Days to Cover

Genenta Science has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genenta Science has recently increased by 39.29%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genenta Science does not currently pay a dividend.

Dividend Growth

Genenta Science does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.03% of the float of Genenta Science has been sold short.

Short Interest Ratio / Days to Cover

Genenta Science has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genenta Science has recently increased by 39.29%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.23

News Sentiment

Genenta Science has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Genenta Science this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Genenta Science to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genenta Science insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.99% of the stock of Genenta Science is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.13% of the stock of Genenta Science is held by institutions.

GNTA Stock Analysis - Frequently Asked Questions

How have GNTA shares performed this year?

Genenta Science's stock was trading at $4.35 at the beginning of 2025. Since then, GNTA stock has decreased by 9.0% and is now trading at $3.96.

When did Genenta Science IPO?

Genenta Science (GNTA) raised $28 million in an initial public offering (IPO) on Wednesday, December 15th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share.

How do I buy shares of Genenta Science?

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genenta Science own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genenta Science investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), PDD (PDD) and AppLovin (APP).

Company Calendar

• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNTA
• CIK: 1838716
• Web: www.genenta.com
• Phone: 39-02-2643-4681
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Genenta Science: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +531.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.89
• Quick Ratio: 6.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.74 per share
• Price / Book: 5.35

Miscellaneous

• Outstanding Shares: 18,290,000
• Free Float: 12,988,000
• Market Cap: $72.43 million
• Optionable: Not Optionable
• Beta: 0.59